Recombinant Human Osteoprotegerin/TNFRSF11B Protein


There are currently no images for Osteoprotegerin/TNFRSF11B (185-OS).

Every product we sell is backed by Novus' 100% Guarantee. If you have used this product, please submit your images and reviews to earn reward points.

Product Details

Reactivity HuSpecies Glossary
Applications Bioactivity

Order Details

View Available Formulations
Catalog# & Formulation Size Price

Recombinant Human Osteoprotegerin/TNFRSF11B Protein Summary

Additional Information
A New and Improved rh OPG is Now Available! The new protein has ~2 fold better activity!
Details of Functionality
Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is 8‑24 ng/mL.
Mouse myeloma cell line, NS0-derived human Osteoprotegerin/TNFRSF11B protein
Accession #
N-terminal Sequence
Structure / Form
Disulfide-linked homodimer
Protein/Peptide Type
Recombinant Proteins
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<0.10 EU per 1 μg of the protein by the LAL method.


  • Bioactivity
Theoretical MW
43.5 kDa (monomer).
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
55 kDa, reducing conditions
Read Publications using
185-OS in the following applications:

Packaging, Storage & Formulations

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Reconstitution Instructions
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.


This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human Osteoprotegerin/TNFRSF11B Protein

  • OCIF
  • OCIFMGC29565
  • OPG
  • OPGtumor necrosis factor receptor superfamily member 11B
  • Osteoclastogenesis inhibitory factor
  • Osteoprotegerin
  • TR1
  • tumor necrosis factor receptor superfamily, member 11b


Osteoprotegerin (OPG), also called OCIF (osteoclastogenesis inhibitory factor) is a secreted 55-60 kDa protein that regulates bone density (1-3). As a member of the tumor necrosis factor receptor (TNFR) superfamily of proteins, it is designated TNFRSF11B (1-4). Human OPG cDNA encodes 401 amino acids (aa) including a 21 aa signal peptide and a 380 aa mature soluble protein with four TNFR domains, two death domains and a heparin-binding region (4). The cysteine-rich TNFR domains are essential for ligand interaction, while a cysteine at the C-terminus mediates homodimerization (4). Mature human OPG shares 86%, 87%, 92%, 92% and 88% amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells (1, 2, 5, 7). Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age (2). OPG has been called a decoy receptor for the TNF superfamily ligands, TRANCE (tumor necrosis factor-related activation-induced cytokine), also called RANK L (receptor activator of NF kappa B ligand), and TRAIL (TNF-related apoptosis-inducing ligand), which also bind TNF family receptors RANK and TRAIL receptors 1-4, respectively (2, 6). TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis (5, 6). Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms (7). Within osteoblasts, interaction of the basic domain of OPG with RANK L in the Golgi inhibits RANK L secretion (7). Extracellularly, OPG binding to RANK L results in clathrin-mediated internalization and degradation of both proteins (7, 8). Binding of OPG by syndecan-1 heparin sulfates on multiple myeloma cells also results in OPG internalization and degradation, contributing to bone loss (8, 9). OPG deficiency can cause juvenile Paget’s disease in humans, and insufficient OPG to balance with RANK L and RANK can produce osteoporosis and vascular calcification in both mice and humans (2, 10, 11).

  1. Simonet, W.S. et al. (1997) Cell 89:309.
  2. Trouvin, A-P. and V. Goeb 2010) Clin. Interv. Aging 5:345.
  3. Yasuda, H. et al. (1998) Proc. Natl. Acad. Sci. USA 95:3597.
  4. Yamaguchi, K. et al. (1998) J. Biol. Chem. 273:5117.
  5. Corallini, F. et al. (2010) J. Cell. Physiol. Dec. 6 [Epub ahead of print].
  6. Emery, J.G. et al. (1998) J. Biol. Chem. 273:14363.
  7. Aoki, S. et al. (2010) J. Bone Miner. Res. 25:1907.
  8. Tat, S.K. et al. (2006) Bone 39:706.
  9. Standal, T. et al. (2002) Blood 100:3002.
  10. Whyte, M.P. et al. (2002) N. Engl. J. Med. 347:175.
  11. Van Campenhout, A. and J. Golledge (2009) Atherosclerosis 204:321.

Customers Who Viewed This Item Also Viewed...

Species: Mu
Applications: BA
Species: Av, Hu, Mu, Rt
Applications: CyTOF-ready, Flow-CS, Flow, IHC, IHC-P, WB
Species: Hu, Rt
Applications: CyTOF-ready, ICC, IHC, ICFlow
Species: Hu
Applications: IHC, WB
Species: Hu
Applications: ELISA
Species: Hu, Mu
Applications: ICC/IF, IHC, IHC-P
Species: Ca, Hu, Mu, Po, Pm, Rt(-)
Applications: Dual ISH-IHC, ICC/IF, IHC, IHC-Fr, IHC-P, IP, KO, PLA, WB
Species: Mu
Applications: ELISA(Cap), ELISA(Det), ELISA(Sta), ICC, IHC, Neut, WB
Species: Hu
Applications: BA
Species: Hu
Applications: ELISA
Species: Hu
Applications: ELISA, AP, PA, WB
Species: Hu
Applications: Flow, ICC/IF, IHC, IHC-P, IP, WB
Species: Hu, Mu
Applications: IHC, IHC-P, WB
Species: Hu, Mu, Rt
Applications: ELISA, S-ELISA, WB
Species: Hu
Applications: IHC, IHC-P
Species: Mu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Hu
Applications: Bioactivity

Publications for Osteoprotegerin/TNFRSF11B (185-OS)(12)

We have publications tested in 4 confirmed species: Human, Mouse, Rat, Porcine.

We have publications tested in 3 applications: Bioassay, Direct ELISA, In Vivo.

Filter By Application
Direct ELISA
In Vivo
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 12. Show All 12 Publications.
Publications using 185-OS Applications Species
E Vorkapic, A Kunath, D Wågsäter Effects of osteoprotegerin/TNFRSF11B in two models of abdominal aortic aneurysms Mol Med Rep, 2018-04-27;0(0):. 2018-04-27 [PMID: 29749489] (In Vivo, Mouse) In Vivo Mouse
CJ Williams, U Qazi, M Bernstein, A Charniak, C Gohr, E Mitton-Fit, A Ortiz, L Cardinal, AT Kaell, AK Rosenthal Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease Osteoarthr. Cartil., 2018-03-22;0(0):. 2018-03-22 [PMID: 29578045] (Bioassay, Porcine) Bioassay Porcine
M Diedisheim, M Oshima, O Albagli, CW Huldt, I Ahlstedt, M Clausen, S Menon, A Aivazidis, AC Andreasson, WG Haynes, P Marchetti, L Marselli, M Armanet, F Chimienti, R Scharfmann Modeling human pancreatic beta cell dedifferentiation Mol Metab, 2018-02-08;0(0):. 2018-02-08 [PMID: 29472102] (Bioassay, Human) Bioassay Human
Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piche A Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis. J Ovarian Res, 2013-11-23;6(1):82. 2013-11-23 [PMID: 24267510] (Bioassay, Human) Bioassay Human
Feng Z, He Z, Zhang B, Chen Z Osteoprotegerin promotes the proliferation of chondrocytes and affects the expression of ADAMTS-5 and TIMP-4 through MEK/ERK signaling. Mol Med Rep, 2013-10-08;8(6):1669-79. 2013-10-08 [PMID: 24126801] (Bioassay, Rat) Bioassay Rat
Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, Ribas A, Li J, Moffat J, Sutherlin DP, Koeppen H, Merchant M, Neve R, Settleman J Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-07-26;487(7408):505-9. 2012-07-26 [PMID: 22763448] (Bioassay, Human) Bioassay Human
Mabilleau G, Sabokbar A Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. PLoS ONE, 2009-01-12;4(1):e4173. 2009-01-12 [PMID: 19137064] (Direct ELISA, Human) Direct ELISA Human
Chamoux E, Houde N, L'Eriger K, Roux S Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J. Cell. Physiol., 2008-08-01;216(2):536-42. 2008-08-01 [PMID: 18338379] (Bioassay, Human) Bioassay Human
Locklin RM, Federici E, Espina B, Hulley PA, Russell RG, Edwards CM Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol. Cancer Ther., 2007-12-07;6(12):3219-28. 2007-12-07 [PMID: 18065493] (Bioassay, Human) Bioassay Human
Secchiero P, Corallini F, Rimondi E, Chiaruttini C, di Iasio MG, Rustighi A, Del Sal G, Zauli G Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells. Blood, 2007-11-13;111(3):1287-94. 2007-11-13 [PMID: 18000166] (Bioassay, Human) Bioassay Human
Show All 12 Publications.

Reviews for Osteoprotegerin/TNFRSF11B (185-OS) (0)

There are no reviews for Osteoprotegerin/TNFRSF11B (185-OS). By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
  • Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
  • Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen

FAQs for Osteoprotegerin/TNFRSF11B (185-OS) (0)

There are no specific FAQs related to this product. Read our general customer & technical service FAQs.

Additional Osteoprotegerin/TNFRSF11B Products

Bioinformatics Tool for Osteoprotegerin/TNFRSF11B (185-OS)

Discover related pathways, diseases and genes to Osteoprotegerin/TNFRSF11B (185-OS). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for Osteoprotegerin/TNFRSF11B (185-OS)

Discover more about diseases related to Osteoprotegerin/TNFRSF11B (185-OS).

Pathways for Osteoprotegerin/TNFRSF11B (185-OS)

View related products by pathway.

PTMs for Osteoprotegerin/TNFRSF11B (185-OS)

Learn more about PTMs related to Osteoprotegerin/TNFRSF11B (185-OS).

Blogs on Osteoprotegerin/TNFRSF11B

There are no specific blogs for Osteoprotegerin/TNFRSF11B, but you can read our latest blog posts.

Customers Who Bought This Also Bought

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Review this Product

Be the first to review our Recombinant Human Osteoprotegerin/TNFRSF11B Protein and receive a gift card or discount.


Gene Symbol TNFRSF11B